FDA-cleared profile

TeraRecon Neuro

TeraRecon, Inc · CT/CTA; MRI · FDA-cleared (510(k))

Authorized purpose: Analyzes functional, dynamic, and derived CT or MRI datasets for brain perfusion, vascular assessment, tissue blood volume, and related parametric maps to assist physician diagnosis.

Clinical role
Software that applies motion correction and calculates brain perfusion analysis results from dynamic CT or MRI datasets, delivering DICOM results to image viewing systems such as PACS to assist the physician in diagnosis.
Images and patients
CT/CTA; MRI · Brain
Key limitation
Keep in mind: Use by trained users; physician judgment and final patient-management decisions remain required; CT-only restriction applies to Tmax, mismatch, and hypoperfusion maps.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Analyzes functional, dynamic, and derived CT or MRI datasets for brain perfusion, vascular assessment, tissue blood volume, and related parametric maps to assist physician diagnosis.
  • Which images or clinical context are in scope?Modality: CT/CTA; MRI Anatomy or clinical context: Brain Input: Functional, dynamic, and derived CT/MRI image data, including dynamic brain-perfusion data, acquired via DICOM-compliant imaging devices.
  • Who uses it?Intended users: Trained professionals, including physicians, surgeons, and medical clinicians.
  • What does the software produce?Output: Perfusion parameter maps (TTP, TOT, RT, MTT, BV/CBV, BF/CBF, Tmax), mismatch/hypoperfusion maps with volumes and ratios, and 2D/3D brain and vessel visualization; Tmax, mismatch, and hypoperfusion maps are CT-only.
  • What is its most important limitation?Key limitation: Use by trained users; physician judgment and final patient-management decisions remain required; CT-only restriction applies to Tmax, mismatch, and hypoperfusion maps.

Clinical takeaway. Clinical role: Analyzes functional, dynamic, and derived CT or MRI datasets for brain perfusion, vascular assessment, tissue blood volume, and related parametric maps to assist physician diagnosis.

Evidence takeaway. Evidence from the reviewed source record: FDA reports software testing, quantitative phantom testing, qualitative clinical user evaluation, and quantitative Tmax comparison; sample size and sensitivity/specificity are not reported.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Analyzes functional, dynamic, and derived CT or MRI datasets for brain perfusion, vascular assessment, tissue blood volume, and related parametric maps to assist physician diagnosis.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.

Workflow role
Software that applies motion correction and calculates brain perfusion analysis results from dynamic CT or MRI datasets, delivering DICOM results to image viewing systems such as PACS to assist the physician in diagnosis.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "TeraRecon Neuro allows motion correction and processes, calculates and outputs brain perfusion analysis results for functional, dynamic, and derived imaging datasets acquired with CT or MRI." … "or other image viewing systems like PACS that can support DICOM results generated by the TeraRecon Neuro Algorithm.". Read from the exact FDA decision document on 2026-11-14.

Required input
Functional, dynamic, and derived CT/MRI image data, including dynamic brain-perfusion data, acquired via DICOM-compliant imaging devices.
  • Exact FDA submission
  • Checked 2026-09-19

FDA input scope.

Output and clinician action
Perfusion parameter maps (TTP, TOT, RT, MTT, BV/CBV, BF/CBF, Tmax), mismatch/hypoperfusion maps with volumes and ratios, and 2D/3D brain and vessel visualization; Tmax, mismatch, and hypoperfusion maps are CT-only.
  • Exact FDA submission
  • Checked 2026-09-19

FDA output description.

Intended users
Trained professionals, including physicians, surgeons, and medical clinicians.
  • Exact FDA submission
  • Checked 2026-09-19

FDA intended-user statement.

Limitations
Use by trained users; physician judgment and final patient-management decisions remain required; CT-only restriction applies to Tmax, mismatch, and hypoperfusion maps.
  • Exact FDA submission
  • Checked 2026-09-19

FDA-labeled use boundary; no broader performance or deployment claim is made.

Evidence summary
FDA reports software testing, quantitative phantom testing, qualitative clinical user evaluation, and quantitative Tmax comparison; sample size and sensitivity/specificity are not reported.
  • Exact FDA submission
  • Checked 2026-09-19

Submission-reported FDA evidence summary, not independent validation.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA reports software testing, quantitative phantom testing, qualitative clinical user evaluation, and quantitative Tmax comparison; sample size and sensitivity/specificity are not reported.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Submission-reported FDA evidence summary, not independent validation.

Reported sensitivity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

Reported specificity
Research pending
  • Needs research
  • Exact FDA submission
  • Checked 2026-08-31

This field has not been curated yet.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

TeraRecon Neuro regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationPopulation described in the exact-submission ACR model card
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K220349
  • IndependenceIndependence not established

K220349

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K220349. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-09
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Functional, dynamic, and derived CT/MRI image data, including dynamic brain-perfusion data, acquired via DICOM-compliant imaging devices.

    Scope: Exact FDA submission. FDA input scope.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K220349: TeraRecon Neuro

  2. Routing

    Source context, not route validation: The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.

    Scope: Exact FDA submission. Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-01 · TeraRecon Neuro model card (K220349)

  3. AI processing

    Source context, not route validation: Cloud-based deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-01 · TeraRecon Neuro model card (K220349)

  4. Returned objects

    Source context, not route validation: Perfusion parameter maps (TTP, TOT, RT, MTT, BV/CBV, BF/CBF, Tmax), mismatch/hypoperfusion maps with volumes and ratios, and 2D/3D brain and vessel visualization; Tmax, mismatch, and hypoperfusion maps are CT-only.

    Scope: Exact FDA submission. FDA output description.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K220349: TeraRecon Neuro

  5. Viewer/worklist/report

    Unresolved route: Perfusion parameter maps (TTP, TOT, RT, MTT, BV/CBV, BF/CBF, Tmax), mismatch/hypoperfusion maps with volumes and ratios, and 2D/3D brain and vessel visualization; Tmax, mismatch, and hypoperfusion maps are CT-only.

    Scope: Exact FDA submission. FDA output description.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K220349: TeraRecon Neuro

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Cloud-based deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Deployment mode explicitly reported in the exact-submission ACR model card; hosting region and current commercial configuration still require vendor confirmation.

Integration
The exact-submission ACR model card explicitly references DICOM and PACS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-09-01

Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.

Security
TeraRecon announces it has been recognized as an ISO 27001:2022 certified company, maintaining an information security management system with documented processes for managing sensitive company information, HR processes, and IT systems; the announcement names TeraRecon's Intuition product and Eureka Clinical AI platform.
  • Vendor-wide
  • Checked 2026-10-27

Vendor statement; the certificate was not read (a certificate PDF is hosted on the same owning domain). Applicant name variants (TeraRecon Inc. with punctuation/case variants) are bridged via the identical distinctive name. Exact-release scope is not established.

Input or output interoperability

DICOM is explicitly referenced in the described input, output, or workflow.

exact submission · checked 2026-09-01

The model card does not establish every supported DICOM object, transfer method, or local interface.

Deployment model

Cloud-based deployment is explicitly described in the exact-submission ACR model card; hosting region, data flow, and current commercial configuration require vendor confirmation.

exact submission · checked 2026-09-01

Supported acquisition environment

Scanner manufacturers: All

exact submission · checked 2026-09-01

Confirm currently supported software versions, protocols, and site-specific acquisition configurations.

ACR exact-submission catalog context

ACR AI Central provides an exact-submission model card for TeraRecon Neuro; FDA labeling remains controlling for clinical use, limitations, and performance.

exact submission · checked 2026-09-09
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K220349
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
CT/CTA; MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

FDA states CT or MRI; normalized to the controlled catalog enum.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

FDA packet scopes the body part to the head and entire brain.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2022-08-12
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
24Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Care setting: Not yet reviewed - checked 2026-08-31 - Exact FDA submission

    Confirm the intended care setting, patient population, and service line.

  • Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission

    No public price or quote for the exact K220349 configuration was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-09 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

8 sources - 3 history items

Source ledger

  1. FDA K220349: TeraRecon Neuro

    U.S. Food and Drug Administration - Published 2022-08-12 - Accessed 2026-09-09

    Scope: identity, clinicalUse, modality, anatomy, workflow, evidence, implementation, purpose, intendedUsers, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. TeraRecon Neuro model card (K220349)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, output, limitations, evidenceSummary, integration, deployment, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. openFDA exact recall query for K220349

    U.S. Food and Drug Administration - Accessed 2026-09-09

    Scope: postmarketSafety

  8. TeraRecon: ISO 27001:2022 Certification Announcement

    TeraRecon - Published 2023-05-30 - Accessed 2026-10-27

    Scope: security

Research history

  1. K220349 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K242781

cvi42 Software Application

Circle Cardiovascular Imaging Inc.

Authorized purpose: View, post-process, and qualitatively and quantitatively evaluate cardiovascular MR and CT images in DICOM format to obtain diagnostic information as part of a comprehensive diagnostic decision-making process.

Modality
CT/CTA; MRI
Anatomy
Cardiovascular system; heart, coronary and adjacent vessels, and cardiac valves
Decision
2024-10-15
FDA-cleared K231683

inHEART Models

inHEART, SAS

Authorized purpose: Create, review, analyze, annotate, export, and use 3D cardiac models to support reading, reporting, and therapeutic-intervention planning.

Modality
CT/CTA; MRI
Anatomy
Cardiac structures, including the aorta, atria, ventricles, pulmonary artery trunk, and right atrium/inferior vena cava structures described in the FDA performance table
Decision
2024-02-29
FDA-cleared K233568

Ceevra Reveal 3+

Ceevra, Inc.

Authorized purpose: Process, review, analyze, communicate, and exchange multidimensional CT or MR images, including preliminary segmentation of normal anatomy, for preoperative surgical planning and intraoperative display; healthcare professionals make all final patient-management decisions. Machine-learning algorithms are for adults aged 22 years and older, while images for patients under 22 or of unknown age are generated without machine learning.

Modality
CT/CTA; MRI
Anatomy
Multi-region normal anatomy represented in CT or MR images; validated examples include prostate, bladder, neurovascular bundles, kidney, artery, and vein
Decision
2023-12-05
FDA-cleared K213998

cvi42 Auto Imaging Software Application

Circle Cardiovascular Imaging Inc

Authorized purpose: Viewing, post-processing, qualitative and quantitative evaluation, cardiac measurements, calcium scoring, and evaluation of physician-identified vascular lesions in cardiovascular MR/CT images.

Modality
CT/CTA; MRI
Anatomy
Heart and adjacent cardiovascular vessels
Decision
2022-07-28

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history